Story
Aspen Pharmacare Receives Health Canada Approval for Generic Ozempic
Aspen Pharmacare (JSE:APN) announced Monday that its Canadian subsidiary received regulatory approval from Health Canada for Aspen-Semaglutide, a generic version of Novo Nordisk’s widely used diabetes drug, Ozempic.
Approval and Market Context
Health Canada authorized the generic drug for the management of type 2 diabetes, according to the company's statement. The approval for Africa's largest pharmaceutical company follows the expiry of Novo Nordisk's patent for semaglutide in Canada, a development that opens the market to competition from several generic drugmakers.
Semaglutide is the active pharmaceutical ingredient (API) in Novo Nordisk's blockbuster GLP-1 drugs, which include Ozempic for diabetes and Wegovy for weight loss. The introduction of generic alternatives is expected to impact the competitive landscape for these high-demand treatments.
AdLaunch Timeline Dependent on Supply
The timing of Aspen's commercial launch in the Canadian market remains conditional. The company specified that its ability to bring the product to market depends on securing a stable supply of the semaglutide API from its partner, India-based Dr. Reddy’s Laboratories (NSE:REDY).
An API is the core component of a drug that produces its intended therapeutic effect. Supply chain logistics for these key ingredients are a critical factor for generic manufacturers entering a new market.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.